Comparison of Therapeutic Potential of Cytokines
Biological response modifiers (BRMs) are those agents or approaches that influence the relationship between the tumor and host by modifying the hosts response to tumor cells, with resultant therapeutic activity (9). A series of studies with recombinant cytokines designed to better understand their immunomodulatory and therapeutic properties have been undertaken. The present report discusses recombinant murine interferon-gamma (rM IFN-g), recombinant human tumor necrosis factor (rH TNF), rH interleukin-2 (rH IL-2), and rM colony stimulating factor-gm (rM CSF-gm). We discuss the development of Optimal Therapeutic Protocols (OTP) for preclinical studies and initial clinical trials that have been initiated to test the resultant clinical hypotheses.
KeywordsMaximum Tolerate Dose Therapeutic Activity Hairy Cell Leukemia Biological Response Modifier Effector Cell Activity
Unable to display preview. Download preview PDF.
- 1.P. L. Black, H. Phillips, H. Tribble, R. Pennington, M. Schneider, and J. E. Talmadge, Immune responses in tumor-bearing organs and therapeutic activity of rM IFN-G, Fed. Proc. 46: 1499 (1987).Google Scholar
- 5.M. S. Ernstoff, S. Reich, Y. Nishoda, and J. M. Kirkwood, Immunological assessment of melanoma patients treated with recombinant interferon gamma (rIFN-gamma, Biogen, Inc., Cambridge, MA) in a phase I/II trial, Proc. M. Assoc. Cancer Res. 26: 280 (1985).Google Scholar
- 6.D. Hartmann, J. S. Adams, A. K. Meeker, M. A. Schneider, B. F. Lenz, and J. E. Talmadge, Dissociation of therapeutic and toxic effects of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethyl cellulose in tumor-bearing mice. Cancer Res. 46: 1331–1338 (1986).PubMedGoogle Scholar
- 8.A. E. Maluish, W. J. Urba, K. Gordon, W. R. Overton, D. Coggin, E. R. Crisp, R. Williams, and S. A. Sherwin, Determination of an optimum biological response modifying (BRM) dose of interferon gamma in melanoma patients, Proc. Am. Soc. Clin. Oncol. in press (1987).Google Scholar
- 9.E. Mihich and A. Fefer, Biological response modifiers subcommittee report, in: “National Cancer Institute Monograph” 63:1–278 (1983).Google Scholar
- 10.S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, and J. M. Skibber, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Eng. J. Med. 313: 1485–1492 (1985).CrossRefGoogle Scholar
- 13.J. E. Talmadge, H. Phillips, J. Schindler, H. Tribble, and R. Pennington, A systematic preclinical study on the therapeutic properties of rH IL-2 for the treatment of metastatic disease. Cancer Res, in press (1987).Google Scholar
- 14.J. E. Talmadge, H. R. Tribble, R. W. Pennington, H. Phillips, and R. H. Wiltrout, Immunomodulatory and immunotherapeutic properties of recombinant gamma interferon and recombinant tumor necrosis factor in mice. Cancer Res, in press (1987).Google Scholar
- 15.W. H. West, K. W. Tauer, J. R. Yarnelli, G. L. Marshall, D. W. Orr, G. B. Thurman, and R. K. Oldham, Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer, Biol. Ther. Cancer A 1986 Update.Google Scholar